Tag: oncology precision medicine market share

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Oncology Precision Medicine Market Value Growth And Long-Term Outlook

The oncology precision medicine market has experienced substantial growth in recent years. Its valuation is projected to increase from $125.14 billion in 2025 to $141.22 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 12.9%. Historically, this market’s expansion was driven by factors such as the restricted accessibility of genomic testing, the prevailing reliance on conventional chemotherapy protocols, a rise in cancer incidence, the nascent stages of molecular diagnostics, and the implementation of oncology research initiatives within hospitals.

The oncology precision medicine market is anticipated to undergo swift expansion over the coming years. This market is projected to attain a valuation of $226.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.5%. This growth during the forecast period is fueled by progress in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, escalating investments in precision oncology research, the integration of bioinformatics and AI into clinical decision-making, and the wider adoption of biomarker-guided clinical trials. Prominent trends for the forecast period encompass the increasing acceptance of personalized cancer treatments, a rise in the utilization of companion and molecular diagnostics, advancements in liquid biopsy and next-generation sequencing assays, the broadening application of targeted therapeutics and monoclonal antibodies, and an enhanced focus on biomarker-based patient stratification.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=96968561&type=smp&name=Oncology%20Precision%20Medicine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oncology Precision Medicine Market Demand Drivers Opening New Revenue Streams

The increasing occurrence of cancer is projected to drive the expansion of the oncology precision medicine market in the future. Cancer is characterized by the uncontrolled proliferation of anomalous cells, which can metastasize to various body regions, thereby impairing typical physiological processes. This rise in cancer prevalence is attributed to aging demographics, where extended longevity results in the buildup of deoxyribonucleic acid (DNA) mutations, impaired repair mechanisms, persistent inflammation linked to aging, declining immune monitoring, and cellular surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits in cancer treatment by delivering tailored therapies that consider the distinct genetic profile of individual tumors, thereby enhancing efficacy and minimizing adverse reactions. For example, data from February 2024, provided by the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicated that the approximate 20 million new cases of cancer in 2022 are anticipated to surge by 77%, reaching more than 35 million cases by 2050. Consequently, the expanding incidence of cancer serves as a primary impetus for the growth of the oncology precision medicine market.

Oncology Precision Medicine Market Segment Analysis Spotlighting Growth Areas

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Oncology Precision Medicine Market Trends Powering Strategic Industry Growth

Leading entities within the oncology precision medicine market are concentrating on advancing novel solutions, including molecular tumor board initiatives, to promote multidisciplinary cooperation and refine personalized treatment strategies. Molecular tumor boards are expert teams from various disciplines that assess and interpret complex genetic and molecular test results to advise on personalized cancer treatment approaches. For instance, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, introduced the Precision Care Companion initiative. This program was launched to bolster biomarker-driven cancer care by offering education, technological upgrades, and operational aid to oncology practices. This extensive program convenes physicians, clinical staff, business leaders, and pharmaceutical partners to foster a collaborative setting, which accelerates the integration of advanced genomic testing and targeted therapies, thereby enabling providers to offer more personalized and effective cancer treatments while simultaneously improving patient outcomes.

Oncology Precision Medicine Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

View The Full Oncology Precision Medicine Market Report:

https://thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Oncology Precision Medicine Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Oncology Precision Medicine Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for precision oncology has seen swift expansion over recent years. Its value is projected to rise from $125.14 billion in 2025 to $141.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.9%. This historical growth has been driven by factors such as restricted access to genomic testing, continued dependence on conventional chemotherapy approaches, a growing incidence of cancer, the early phases of molecular diagnostic advancement, and the implementation of research initiatives focused on oncology within hospital settings.

The oncology precision medicine market is projected to experience significant expansion over the coming years, reaching an estimated value of $226.55 billion by 2030, driven by a compound annual growth rate (CAGR) of 12.5%. This anticipated growth during the forecast period is fueled by progress in CAR-T and gene therapies, the expansion of targeted kinase and immune checkpoint inhibitors, increased funding for precision oncology research, the incorporation of bioinformatics and artificial intelligence into clinical decision-making, and the broadening of biomarker-guided clinical trials. Key trends shaping this period include a growing preference for personalized cancer treatments, heightened utilization of companion diagnostics and molecular diagnostics, the rise of liquid biopsy and next-generation sequencing assays, the proliferation of targeted therapeutics and monoclonal antibodies, and an intensified emphasis on patient stratification based on biomarkers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Oncology Precision Medicine Market Growth Factors: Which Forces Are Supporting Market Expansion?

The rising incidence of cancer is anticipated to boost the oncology precision medicine market in the coming period. Cancer is a condition where abnormal cells proliferate without control and may invade other parts of the body, interfering with normal physiological processes. Its increasing frequency is driven by aging populations, as longer lifespans result in the buildup of DNA mutations, weakened repair mechanisms, chronic inflammaging, reduced immune surveillance, and tissue environments that become more favorable for tumor development. In this context, oncology precision medicine proves valuable by delivering tailored therapies that target each tumor’s distinct genetic profile, thereby enhancing treatment efficacy while minimizing adverse effects. By way of illustration, the World Health Organization (WHO), an intergovernmental body based in Switzerland, reported in February 2024 that the estimated 20 million new cancer cases globally in 2022 are projected to surge by 77% to over 35 million cases by 2050. Consequently, the growing prevalence of cancer is fueling expansion in the oncology precision medicine market.

Oncology Precision Medicine Market Segmentation Trends And Revenue Drivers

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Oncology Precision Medicine Market Industry Trends: What Changes Are Reshaping Demand?

Major players in the oncology precision medicine field are actively concentrating on the creation of advanced tools, including molecular tumor board setups, aimed at improving teamwork across disciplines and refining personalized therapy approaches. These boards consist of diverse groups of specialists that assess and decode complex hereditary and molecular information to propose customized cancer management plans. In April 2025, for example, McKesson Corporation, headquartered in the United States and specializing in healthcare services and IT, unveiled the Precision Care Companion project to boost biomarker-focused cancer care via educational resources, technological upgrades, and operational support for oncology clinics. This extensive effort unites medical professionals, clinical teams, business executives, and pharmaceutical collaborators to build a cooperative framework that accelerates the adoption of sophisticated genomic analysis and targeted treatments, ultimately assisting clinicians in providing more tailored and effective cancer care while enhancing patient experiences.

Oncology Precision Medicine Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Access The Complete Oncology Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Oncology Precision Medicine Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Oncology Precision Medicine Market Become By 2030 Compared To 2026?

The oncology precision medicine market size has seen significant expansion in recent years. It is projected to grow from $125.14 billion in 2025 to $141.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. The growth observed in the historical period was driven by factors such as the limited availability of genomic testing, the reliance on standard chemotherapy protocols, the increasing prevalence of cancer, the early development of molecular diagnostics, and the adoption of hospital-based oncology research programs.

The oncology precision medicine market is anticipated to undergo significant expansion in the next few years. It is forecasted to achieve a size of **$226.55 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%**. The growth expected within this period can be attributed to advancements in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, rising investments in precision oncology research, the integration of bioinformatics and AI in clinical decision-making, and the expansion of biomarker-guided clinical trials. Prominent trends for the forecast period include a rising adoption of personalized cancer therapies, increasing use of companion diagnostics and molecular diagnostics, growth in liquid biopsy and next-generation sequencing assays, expansion of targeted therapeutics and monoclonal antibodies, and an increasing focus on biomarker-based patient stratification.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Market Drivers Are Helping Shape The Oncology Precision Medicine Market Expansion?

The increasing occurrence of cancer is projected to fuel the expansion of the oncology precision medicine market moving ahead. Cancer is characterized by the uncontrolled proliferation of abnormal cells, which can disseminate throughout the body and interfere with regular physiological processes. This rise in cancer prevalence is attributed to aging populations, where extended lifespans contribute to the buildup of deoxyribonucleic acid (DNA) mutations, impaired cellular repair mechanisms, persistent low-grade inflammation (chronic inflammaging), reduced immune oversight, and tissue surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits for cancer treatment by delivering individualized therapies tailored to the specific genetic profile of each tumor, thereby enhancing efficacy and mitigating adverse reactions. For example, in February 2024, data from the World Health Organization (WHO), a Switzerland-based intergovernmental body, indicated that the approximately 20 million new cancer cases in 2022 are anticipated to surge by 77% to exceed 35 million cases by 2050. Consequently, the increasing incidence of cancer is propelling the expansion of the oncology precision medicine market.

How Is The Oncology Precision Medicine Market Examined Through Segment Analysis?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Which Trends Are Expected To Shape The Oncology Precision Medicine Market?

Major companies within the oncology precision medicine market are concentrating on developing innovative solutions, including molecular tumor board programs, to aid multidisciplinary cooperation and enhance personalized treatment strategies. Molecular tumor boards are multidisciplinary teams of experts who review and interpret intricate genetic and molecular test results to suggest individualized cancer treatment plans. For instance, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, introduced the Precision Care Companion initiative aimed at supporting biomarker-driven cancer care by offering education, technological upgrades, and operational assistance to oncology practices. This extensive program unites physicians, clinical staff, business leaders, and pharmaceutical partners to foster a collaborative environment that accelerates the incorporation of advanced genomic testing and targeted therapies, ultimately assisting providers in delivering more personalized and effective cancer treatments while simultaneously improving patient outcomes.

Which Companies Form The Competitive Landscape Of The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Access The Complete Oncology Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

Which Region Accounts For The Highest Share Of The Oncology Precision Medicine Market?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncology Precision Medicine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2026, By The Business Research Company

Precision Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Oncology Precision Medicine Market Projected To Reach By 2030?

The oncology precision medicine market size has seen rapid expansion in recent years. It is anticipated to grow from $125.14 billion in 2025 to $141.22 billion in 2026, registering a compound annual growth rate (CAGR) of 12.9%. The historical growth of this market can be attributed to factors such as the limited availability of genomic testing, a reliance on standard chemotherapy protocols, an increasing prevalence of cancer, the early advancements in molecular diagnostics, and the establishment of hospital-based oncology research programs.

The oncology precision medicine market is projected to experience rapid expansion over the coming years, with its valuation anticipated to reach $226.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.5%. This projected growth during the forecast period stems from various factors, including breakthroughs in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, greater investments in precision oncology research, the incorporation of bioinformatics and AI into clinical decision-making processes, and the expansion of biomarker-guided clinical trials. Key trends expected over the forecast period encompass a growing acceptance of personalized cancer therapies, more widespread utilization of companion diagnostics and molecular diagnostics, advancements in liquid biopsy and next-generation sequencing assays, an expansion of targeted therapeutics and monoclonal antibodies, and an intensified focus on patient stratification based on biomarkers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Primary Drivers Are Shaping The Oncology Precision Medicine Market?

The increasing incidence of cancer is projected to fuel the expansion of the oncology precision medicine market in the future. Cancer refers to an illness characterized by the unchecked proliferation of aberrant cells, capable of metastasizing to various bodily regions and impairing typical physiological processes. This rise in cancer prevalence stems from aging demographics, where extended lifespans contribute to the buildup of deoxyribonucleic acid (DNA) mutations, impaired repair mechanisms, persistent inflammaging, declining immune vigilance, and tissue microenvironments that progressively favor tumor development. Oncology precision medicine offers benefits for cancer patients by delivering customized therapies tailored to the distinct genetic profile of individual tumors, thereby enhancing efficacy and minimizing adverse reactions. For example, the World Health Organization (WHO), a Switzerland-based intergovernmental body, reported in February 2024 that the approximately 20 million new cancer cases in 2022 are predicted to surge by 77% to exceed 35 million cases by 2050. Consequently, the escalating occurrence of cancer is a key factor propelling the expansion of the oncology precision medicine market.

What Are The Key Segment Divisions In The Oncology Precision Medicine Market Segment Structure?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

What Market Trends Are Affecting The Oncology Precision Medicine Market?

Key companies within the oncology precision medicine market are concentrating on creating innovative solutions, such as molecular tumor board programs, to encourage multidisciplinary cooperation and refine individualized treatment planning. Molecular tumor boards consist of expert teams from various fields who assess and interpret intricate genetic and molecular test findings to recommend tailored cancer treatment approaches. For example, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, unveiled the Precision Care Companion initiative. This program is designed to support biomarker-driven cancer care by delivering education, technological advancements, and operational aid to oncology practices. This extensive initiative unites physicians, clinical staff, business leaders, and pharmaceutical partners to foster a collaborative setting, which expedites the incorporation of advanced genomic testing and targeted therapies, ultimately enabling providers to deliver more personalized and effective cancer treatments while improving patient outcomes.

Which Organizations Are Engaged In The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Get The Full Oncology Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

Which Region Leads The Oncology Precision Medicine Market In Overall Market Size?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Precision Medicine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2026, By The Business Research Company

Precision Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Oncology Precision Medicine Market At The End Of The 2026–2030 Forecast Period?

The oncology precision medicine market has experienced substantial expansion in recent years. Its valuation is projected to increase from $125.14 billion in 2025 to $141.22 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. This historical growth can be linked to factors such as the limited availability of genomic testing, a reliance on standard chemotherapy protocols, the increasing prevalence of cancer, the early evolution of molecular diagnostics, and the adoption of hospital-based oncology research programs.

The oncology precision medicine market is projected to experience substantial expansion over the upcoming years. This market is set to reach $226.55 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. Key drivers for this anticipated growth include progress in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, greater investments in precision oncology research, the incorporation of bioinformatics and AI into clinical decision support, and the expansion of clinical trials guided by biomarkers. Notable trends identified for the projection period encompass a growing uptake of personalized cancer treatments, enhanced utilization of companion and molecular diagnostics, an expansion in liquid biopsy and next-generation sequencing assays, the proliferation of targeted therapeutics and monoclonal antibodies, and a heightened emphasis on patient stratification based on biomarkers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Primary Drivers Are Shaping The Development Of The Oncology Precision Medicine Market?

The oncology precision medicine market is anticipated to expand due to the increasing incidence of cancer. Cancer involves the uncontrolled proliferation of aberrant cells, which can disseminate throughout the body and impair physiological functions. This rise in cancer cases stems from aging demographics, where extended lifespans contribute to deoxyribonucleic acid (DNA) mutation build-up, less efficient repair mechanisms, persistent inflammation associated with aging, reduced immune monitoring, and tissue environments that increasingly favor tumor development. Oncology precision medicine offers benefits for cancer patients by tailoring treatments according to each tumor’s distinct genetic profile, thereby enhancing efficacy and minimizing adverse reactions. As an illustration, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported in February 2024 that the projected 20 million new cancer cases in 2022 are predicted to surge by 77% to exceed 35 million cases by 2050. Consequently, the escalating occurrence of cancer acts as a key driver for the expansion of the oncology precision medicine market.

What Segment Types Make Up The Oncology Precision Medicine Market?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Which Market Trends Are Creating New Opportunities In The Oncology Precision Medicine Market?

Leading companies in the oncology precision medicine market are concentrating on developing novel solutions, such as molecular tumor board initiatives, to foster multidisciplinary collaboration and enhance personalized treatment planning. Molecular tumor boards are multidisciplinary teams of experts who review and interpret complex genetic and molecular test results to recommend personalized cancer treatment strategies. For instance, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, launched the Precision Care Companion initiative to support biomarker-driven cancer care by providing education, technology enhancements, and operational assistance to oncology practices. This comprehensive program unites physicians, clinical staff, business leaders, and pharmaceutical partners to create a collaborative environment that speeds the integration of advanced genomic testing and targeted therapies, ultimately helping providers deliver more personalized and effective cancer treatments while improving patient outcomes.

Who Are The Key Players Driving Competition In The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Read the full oncology precision medicine market report here:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

How Does The Oncology Precision Medicine Market Perform Across Major Global Regions?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Precision Medicine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2026, By The Business Research Company

Precision Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oncology precision medicine market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Oncology Precision Medicine Market in 2030?

The oncology precision medicine market size has demonstrated rapid expansion in recent years. Projections indicate it will progress from $125.14 billion in 2025 to $141.22 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.9%. The growth observed in prior periods can be linked to the restricted availability of genomic testing, a reliance on standard chemotherapy protocols, the increasing prevalence of cancer, the early advancement of molecular diagnostics, and the implementation of hospital-based oncology research programs.

The market for oncology precision medicine is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $226.55 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.5%. This expansion during the projection period stems from several factors, including breakthroughs in CAR-T and gene therapies, an increase in targeted kinase and immune checkpoint inhibitors, greater investments in precision oncology research, the incorporation of bioinformatics and AI into clinical decision support, and the broadening of biomarker-guided clinical trials. Key developments foreseen in this timeframe encompass the growing acceptance of personalized cancer treatments, a rise in the application of companion and molecular diagnostics, the advancement of liquid biopsy and next-generation sequencing assays, the proliferation of targeted therapeutics and monoclonal antibodies, and an intensified emphasis on biomarker-driven patient grouping.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Drivers Are Influencing Production Trends In The Oncology Precision Medicine Market?

The increasing occurrence of cancer is projected to drive the expansion of the oncology precision medicine market in the future. This illness involves the unchecked proliferation of abnormal cells, which can metastasize throughout the body, interfering with regular physiological processes. The rising incidence of cancer stems from aging demographics, where extended lifespans contribute to the buildup of deoxyribonucleic acid (DNA) mutations, impaired repair mechanisms, persistent low-grade inflammation (inflammaging), compromised immune oversight, and tissue surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits in cancer management through customized therapies tailored to the specific genetic profile of individual tumors, thereby enhancing efficacy and minimizing adverse reactions. For example, data from February 2024, published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, indicates that the estimated 20 million new cancer cases in 2022 are projected to increase by 77%, reaching more than 35 million cases by 2050. Consequently, the expanding occurrence of cancer is fueling the expansion of the oncology precision medicine market.

Which Segments Are Gaining Traction In The Oncology Precision Medicine Market?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

What Trends Are Driving The Growth Trajectory Of The Oncology Precision Medicine Market?

Major companies in the oncology precision medicine market are prioritizing the development of innovative solutions, such as molecular tumor board initiatives, to foster multidisciplinary collaboration and enhance personalized treatment planning. Molecular tumor boards comprise expert teams from various disciplines who assess and interpret intricate genetic and molecular test findings to recommend individualized cancer treatment strategies. As an illustration, in April 2025, McKesson Corporation, a US-based healthcare services and information technology company, introduced its Precision Care Companion initiative. This program is designed to support biomarker-driven cancer care by supplying education, technology upgrades, and operational assistance to oncology practices. The expansive initiative brings together physicians, clinical staff, business leaders, and pharmaceutical partners to cultivate a collaborative environment that expedites the integration of advanced genomic testing and targeted therapies, ultimately assisting providers in delivering more personalized and effective cancer treatments while improving patient outcomes.

Who Are The Major Companies Operating In The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Oncology Precision Medicine Market?

North America was the largest region in the oncology precision medicine market in 2025. The regions covered in the oncology precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncology Precision Medicine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2026, By The Business Research Company

Precision Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Oncology Precision Medicine Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The oncology precision medicine market has experienced substantial growth in recent years. Its value is expected to climb from $110.90 billion in 2024 to $125.14 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 12.8%. This historical expansion can be ascribed to the increasing prevalence of cancer, the growing adoption of targeted therapies, rising investments in genomic research, the expanding healthcare infrastructure, and an increased awareness of personalized medicine.

The oncology precision medicine market is projected to experience substantial expansion in the coming years. It is anticipated to reach $201.40 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This growth throughout the forecast period stems from factors such as a heightened demand for non-invasive cancer diagnostics, a rising inclination towards personalized treatment methods, increased utilization of companion diagnostics, an expanding selection of precision oncology drugs under development, and the growing clinical integration of artificial intelligence tools. Key trends anticipated during this period encompass technological progress in liquid biopsy platforms, breakthroughs in next-generation sequencing, advancements in artificial intelligence for analyzing data, ongoing research and development in identifying biomarkers, and the incorporation of multi-omics into clinical oncology practices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Are The Key Drivers Of Growth In The Oncology Precision Medicine Market?

An increasing incidence of cancer is anticipated to fuel the expansion of the oncology precision medicine market in the coming years. Cancer involves the unchecked proliferation of aberrant cells, capable of spreading throughout the body and impairing regular physiological processes. This rise in cancer cases stems from aging demographics, where extended longevity contributes to the buildup of deoxyribonucleic acid (DNA) mutations, compromised repair mechanisms, persistent inflammaging, declining immune vigilance, and tissue surroundings that increasingly foster tumor development. Oncology precision medicine offers benefits for cancer patients by delivering individualized therapies, tailored to the distinct genetic profile of each tumor, thereby enhancing efficacy and mitigating adverse reactions. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental body, projected that the approximately 20 million new cases of cancer recorded in 2022 are set to increase by 77% to exceed 35 million cases by 2050. Consequently, the increasing occurrence of cancer is a key impetus for the expansion of the oncology precision medicine market.

What Are The Different Segment Classifications Within The Oncology Precision Medicine Market?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

Which Market Trends Are Creating New Opportunities In The Oncology Precision Medicine Industry?

Leading companies in the oncology precision medicine market are dedicating efforts to developing inventive solutions, such as molecular tumor board initiatives, to foster multidisciplinary cooperation and refine personalized treatment planning. Molecular tumor boards are multidisciplinary groups of specialists who assess and interpret complex genetic and molecular test results to propose individualized cancer treatment strategies. For example, in April 2025, McKesson Corporation, a US-based healthcare services and information technology firm, unveiled its Precision Care Companion initiative designed to bolster biomarker-driven cancer care by supplying education, technological improvements, and operational aid to oncology practices. This comprehensive undertaking gathers physicians, clinical staff, business leaders, and pharmaceutical partners to establish a collaborative setting that accelerates the integration of advanced genomic testing and targeted therapies, ultimately enabling providers to deliver more personalized and impactful cancer treatments while enhancing patient outcomes.

Who Are The Key Multinational Companies Dominating The Oncology Precision Medicine Market?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

How Is Oncology Precision Medicine Market Demand Varying Across Different Regions?

North America was the largest region in the oncology precision medicine market in 2024. The regions covered in the oncology precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Oncology Precision Medicine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp

Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2025, By The Business Research Company

Precision Medicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/precision-medicine-global-market-report

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Industry Valuation for the Oncology Precision Medicine Sector?

The size of the oncology precision medicine market has experienced quick growth in the past few years. Its growth trajectory is projected to accelerate from $110.90 billion in 2024 to $125.14 billion in 2025, charting a compound annual growth rate (CAGR) of 12.8%. The growth seen during the historic period is credited to the increasing incidence of cancer, escalating adoption of targeted treatments, larger investment in genetic research, enhanced healthcare infrastructure and growing awareness about individualized medicine.

The market for precision oncology is projected to experience substantial growth in the upcoming years, escalating to a value of $201.40 billion in 2029 with a compound annual growth rate (CAGR) of 12.6%. This accelerated growth during the prediction period can be credited to an escalating demand for non-invasive cancer diagnostic procedures, increased inclination towards personalized treatment modalities, the rising usage of companion diagnostics, the growth of the precision oncology drug pipeline, and more prolific clinical use of artificial intelligence tools. Key trends observed during this period encompass advancements in liquid biopsy technology, novel innovations in next-generation sequencing, progress in artificial intelligence for data analysis, creation of new biomarkers through research and development, and the incorporation of multi-omics in clinical oncology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp

What Forces Are Driving The Growth Of The Oncology Precision Medicine Market?

The continual rise in cancer rates is set to boost the expansion of the oncology precision medicine market. Cancer, a disease characterized by the uncontrolled growth and spread of abnormal cells, can severely disrupt the body’s normal functions. Factors contributing to the increasing cancer rates include ageing populations and the inherent consequences such as the build-up of DNA mutations, breakdown of repair mechanisms, persistent inflammaging, weakened immune surveillance, and alterations in tissue microenvironments that augment tumor progression. Oncology precision medicine significantly contributes to cancer treatment, providing personalized medical approaches tailored to the distinct genetic composition of each tumor, thereby increasing efficacy and limiting side effects. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, projected that the 20 million cancer cases recorded in 2022, are anticipated to surge by 77% to exceed 35 million cases by 2050. Thus, the increasing cancer rates are a key factor propelling the growth of the oncology precision medicine market.

How Is The Oncology Precision Medicine Industry Segmented Across Key Parameters?

The oncology precision medicine market covered in this report is segmented –

1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs

2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies

3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types

4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications

5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays

2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)

4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies

5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies

6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers

What Upcoming Trends Are Expected To Impact The Oncology Precision Medicine Market Globally?

Major players in the oncology precision medicine market, such as molecular tumor board programs, are creating cutting-edge solutions to promote cooperative efforts between multiple disciplines and streamline bespoke treatment planning. Molecular tumor boards consist of interdisciplinary specialists who examine and decode intricate genomic and molecular testing results to suggest individualized cancer treatment approaches. For example, in April 2025, the American healthcare services and IT firm, McKesson Corporation, introduced the Precision Care Companion initiative. Through this program, they aim to back biomarker-led cancer treatment by offering education, technological updates, and administrative support to oncology practices. This exhaustive scheme consolidates doctors, clinical personnel, business heads, and pharma associates to establish a synergistic atmosphere that accelerates the assimilation of sophisticated genomic testing and targeted treatments. This assists in providing more personalized and efficient cancer therapies, thereby enhancing patient outcomes.

Which Companies Currently Dominate The Competitive Landscape In The Oncology Precision Medicine Industry?

Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-precision-medicine-global-market-report

Which Geographic Regions Are Driving Demand In The Oncology Precision Medicine Market?

North America was the largest region in the oncology precision medicine market in 2024. The regions covered in the oncology precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model